Hematologic Malignancy
Lymphoid Neoplasm
CI-CAN-00009335Explore in graph →
Hematologic2,419 active trials60 approved drugs271 evidence items
- OncoTree
- LNM
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00009335Explore in graph →
Clinical trials
8,886 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,374)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00413959 | VELCADE,Rituximab,Cyclophosphamide and Decadron(VRCD) | terminated | Phase 2 | 12 | Oncology Specialists, S.C.OTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
| NCT00918463 | A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT00946023 | Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab | terminated | Phase 2 | 135 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2018 | clinicaltrials |
| NCT00847223 | Efficacy and Safety of the Farnesyl-transferase Inhibitor (Tipifarnib) in Mantle Cell Lymphoma | terminated | Phase 2 | 11 | Lymphoma Study AssociationOTHER | 0 | Aug 23, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00124579 | S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | SWOG Cancer Research NetworkNETWORK | 1 | Aug 9, 2018 | clinicaltrials |
| NCT02720510 | A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)(PANORAMA4) | terminated | Phase 2 | 6 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01745913 | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01779167 | Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia(THRiL for WM) | terminated | Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 11, 2018 | clinicaltrials |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | terminated | Phase 1 / Phase 2 | 3 | Loyola UniversityOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT02419469 | Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2018 | clinicaltrials |
| NCT00664378 | Efficacy Study of CYT997 in Multiple Myeloma | terminated | Phase 2 | 5 | Gilead SciencesINDUSTRY | 1 | Jun 8, 2018 | clinicaltrials |
| NCT00538824 | Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma(DexTR) | terminated | Phase 2 | 5 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01812005 | Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 2 | 14 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01979276 | Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma) | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT02420210 | Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 2 | University of ChicagoOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01174082 | Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant | terminated | Phase 2 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 1, 2018 | clinicaltrials |
| NCT00482053 | Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT | terminated | Phase 2 | 3 | Stanford UniversityOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT02372240 | A Study of VLX1570 and Dexamethasone in Myeloma Patients | terminated | Phase 1 / Phase 2 | 15 | Vivolux ABINDUSTRY | 1 | May 11, 2018 | clinicaltrials |
| NCT02533323 | P-Gemox Regimen as First-line Chemotherapy in NK/T Lymphoma Patiens | terminated | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 9, 2018 | clinicaltrials |
| NCT00290407 | Rituximab Plus Beta-Glucan in Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL) | terminated | Phase 2 | 2 | University of LouisvilleOTHER | 1 | May 4, 2018 | clinicaltrials |
| NCT00984165 | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogeneic Hematopoietic Stem Cell Transplantation | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 2, 2018 | clinicaltrials |
| NCT02877082 | Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients | terminated | Phase 2 | 5 | Emory UniversityOTHER | 1 | Apr 30, 2018 | clinicaltrials |
| NCT00626626 | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation | terminated | Phase 1 / Phase 2 | 8 | Milton S. Hershey Medical CenterOTHER | 1 | Apr 25, 2018 | clinicaltrials |
| NCT02488512 | Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas(itTRIOlym) | terminated | Phase 2 | 1 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT02530125 | Pidilizumab in Treating Patients With Stage III-IV Diffuse Large B-Cell Lymphoma Following First Remission | terminated | Phase 2 | 4 | Northwestern UniversityOTHER | 1 | Mar 19, 2018 | clinicaltrials |
| NCT00113646 | Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 14 | Massachusetts General HospitalOTHER | 1 | Mar 16, 2018 | clinicaltrials |
| NCT00113828 | Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies | terminated | Phase 2 | 5 | Massachusetts General HospitalOTHER | 1 | Mar 15, 2018 | clinicaltrials |
| NCT00354107 | Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01313611 | BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF) | terminated | Phase 2 | 62 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 7, 2018 | clinicaltrials |
| NCT01147393 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00481832 | Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma | terminated | Phase 2 | 50 | Stanford UniversityOTHER | 1 | Feb 14, 2018 | clinicaltrials |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | terminated | Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003500 | Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00003501 | Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma | terminated | Phase 2 | 2 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP(R²-DHAP) | terminated | Phase 1 / Phase 2 | 34 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00455897 | CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma | terminated | Phase 2 | 3 | Massachusetts General HospitalOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT02456675 | INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma | terminated | Phase 2 | 8 | Incyte CorporationINDUSTRY | 0 | Jan 12, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT01636388 | Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma | terminated | Phase 2 | 2 | New York Medical CollegeOTHER | 1 | Dec 22, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01518465 | Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma | terminated | Phase 2 | 13 | University of Southern CaliforniaOTHER | 1 | Nov 29, 2017 | clinicaltrials |
| NCT01969565 | Study of Carfilzomib in Combination w/Dexamethasone in Patients w/Newly Diagnosed Multiple Myeloma | terminated | Phase 2 | 1 | Emory UniversityOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02815397 | DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma(DLBCL) | terminated | Phase 2 | 2 | Rush University Medical CenterOTHER | 1 | Nov 17, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Sep 19, 2018source: clinicaltrials